Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Ziming Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5987-0148; OpenAlex author ID A5050294825. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper · 2025: 6 papers · 2026: 1 paper

Papers 9

  1. NSUN6 deficiency drives immune suppression in pancreatic cancer via the KDM5A-CCL2-macrophage axis. Co-author DOI 10.1136/gutjnl-2025-336541↗
  2. Identification of novel plasma proteins as promising noninvasive biomarker for early diagnosis and surveillance of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-025-02252-w↗
  3. Correction: Identification of novel plasma proteins as promising noninvasive biomarker for early diagnosis and surveillance of pancreatic ductal adenocarcinoma Co-author DOI 10.1007/s00535-025-02274-4↗
  4. Extracellular vesicles from obese visceral adipose promote pancreatic cancer development and resistance to immune checkpoint blockade therapy. Co-author DOI 10.1016/j.cmet.2025.10.015↗
  5. CSTF2-impeded innate αβ T cell infiltration and activation exacerbate immune evasion of pancreatic cancer. Co-author DOI 10.1038/s41418-025-01464-0↗
  6. Psychological stress-induced ALKBH5 deficiency promotes tumour innervation and pancreatic cancer via extracellular vesicle transfer of RNA. Co-author DOI 10.1038/s41556-025-01667-0↗
  7. Targeting MXD1 sensitises pancreatic cancer to trametinib. Co-author DOI 10.1136/gutjnl-2024-333408↗
  8. KHSRP Stabilizes m6A-Modified Transcripts to Activate FAK Signaling and Promote Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1158/0008-5472.can-24-0927↗
  9. N 6-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-3346↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lingxing Zeng · 9 shared papers, 2023–2026 · strength 1.67
  2. Jialiang Zhang · 9 shared papers, 2023–2026 · strength 1.67
  3. Zilan Xu · 9 shared papers, 2023–2026 · strength 1.67
  4. Chunling Xue · 9 shared papers, 2023–2026 · strength 1.67
  5. Xudong Huang · 7 shared papers, 2023–2026 · strength 1.28
  6. Jian Zheng · 6 shared papers, 2023–2025 · strength 1.05
  7. Dongxin Lin · 6 shared papers, 2023–2025 · strength 1.05
  8. Xiaowei He · 5 shared papers, 2023–2025 · strength 0.86
  9. Shaoping Zhang · 5 shared papers, 2023–2025 · strength 0.85
  10. Jiachun Su · 4 shared papers, 2023–2026 · strength 0.76
  11. Quanbo Zhou · 3 shared papers, 2023–2025 · strength 0.49
  12. Shuang Liu · 2 shared papers, 2025 · strength 0.39
  13. Lu Zheng · 2 shared papers, 2025 · strength 0.39
  14. Xiaoyu Wu · 2 shared papers, 2025 · strength 0.38
  15. Rui Li · 2 shared papers, 2023–2024 · strength 0.29
  16. Rufu Chen · 2 shared papers, 2023–2024 · strength 0.29
  17. Qi Zhou · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.